Jesús F. San Miguel

Research interests

Publications

• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

  Blood · 2022 · https://doi.org/10.1182/blood.2022015851

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2024850

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1714678

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · 10.1093/annonc/mdx096

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1607751

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · 10.1182/blood-2016-01-631200

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.61.2267

• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505654

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1411321

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1300439

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

  Blood · 2011 · 10.1182/blood-2010-10-299487

• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  Nature · 2011 · 10.1038/nature10113

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · 10.1038/leu.2011.196

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · 10.1038/leu.2010.60

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0801479

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Leukemia · 2007 · 10.1038/sj.leu.2405062

• Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2007 · 10.1056/nejmoa070594

• International uniform response criteria for multiple myeloma

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404284

• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043445

• International Staging System for Multiple Myeloma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.04.242

• Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

  Seminars in Oncology · 2003 · 10.1053/sonc.2003.50082

• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  Leukemia · 1999 · 10.1038/sj.leu.2401592

Current projects

No projects listed.